Sirigen Group Ltd, a Ringwood, UK-based based medical technology company, has completed two financing rounds totalling £3.83m.
These rounds were led by a syndicate of new investors comprising IQ Capital, NESTA (National Endowment for Science, Technology and the Arts) and YFM Private Equity alongside existing investors, Seraphim Capital and Oxford Capital Partners.
The company intends to use the funds to commercialize its High Sensitivity Fluorescence™ (“HSF™”) technology, designed to boost the performance of in vitro diagnostic tools for diseases including HIV and leukaemia.
In conjunction with the funding, Ivan Griffin of NESTA and Max Bautin of IQ Capital, will join the company’s board. Sirigen also appointed David Evans as Chairman of the Board, and Arthur Cole as Non-Executive Director.
The company is led by CEO Nick Kerton.